Cas:885271-30-7 ethyl 6,8-dibromo-2H-chromene-3-carboxylate manufacturer & supplier

Chemical Name:ethyl 6,8-dibromo-2H-chromene-3-carboxylate

CAS.NO:885271-30-7

Synonyms:6,8-dibromo-2h-chromene-3-carboxylic acid ethyl ester

Molecular Formula:C₁₂H₁₀Br₂O₃

Molecular Weight:362.01400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.53000

Exact Mass:359.90000

LogP:3.55050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6,8-dibromo-2h-chromene-3-carboxylic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6,8-dibromo-2h-chromene-3-carboxylic acid ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6,8-dibromo-2h-chromene-3-carboxylic acid ethyl ester Use and application,6,8-dibromo-2h-chromene-3-carboxylic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. ethyl 6,8-dibromo-2H-chromene-3-carboxylate manufacturer Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. ethyl 6,8-dibromo-2H-chromene-3-carboxylate supplier The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. ethyl 6,8-dibromo-2H-chromene-3-carboxylate vendor Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. ethyl 6,8-dibromo-2H-chromene-3-carboxylate factory The company��s iPSC product platform unites stem cell biology and precision genetic engineering to create renewable master engineered iPSC lines that can be repeatedly used to mass produce cancer-fighting immune cells, replacing the high production costs, weeks of manufacturing time, and complex engineering processes required for current-generation CAR T-cell immunotherapies with an off-the-shelf product that has the potential to reach many more patients.